OpenAI to produce its own AI chip with Broadcom from 2026- FT
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a $7.36 million market cap healthcare company with annual revenues of $14.91 million, held its annual meeting of stockholders on Wednesday. Despite a recent 10% decline in share price, the stock has delivered an impressive 100% return over the past six months, according to InvestingPro data. Four proposals were submitted to a vote at the meeting.
Shareholders elected Dr. Jay Birnbaum as a Class II director. The vote tally was 123,034 shares in favor and 19,478 shares withheld.
An advisory vote to approve executive compensation for the fiscal year ended March 31, 2025, was approved by shareholders. The results were 112,548 shares for, 26,360 against, and 3,604 abstaining.
Stockholders also ratified the appointment of Frazier & Deeter, LLC as the company’s independent registered public accounting firm for the fiscal year ending March 31, 2026. The vote was 702,484 for, 13,569 against, and 2,416 abstaining.
A fourth proposal, authorizing the adjournment of the meeting to solicit additional proxies if necessary, was also approved. The votes were 576,908 in favor, 140,513 against, and 1,048 abstaining.
A total of 718,469 shares were present or represented by proxy at the meeting out of 1,642,765 shares entitled to vote. Each share was entitled to one vote.
These results are based on a press release statement and the company’s 8-K filing with the Securities and Exchange Commission. Sonoma Pharmaceuticals is listed on the Nasdaq Stock Market under the ticker SNOA.
In other recent news, Sonoma Pharmaceuticals has introduced its new diaper rash product across major U.S. retail outlets. The product, which utilizes the company’s patented Microcyn technology featuring stabilized hypochlorous acid, is now available in 3,600 Walmart locations. Additionally, it can be purchased on Amazon.com and in several large grocery chains throughout the United States. This launch marks a significant expansion for Sonoma Pharmaceuticals, as the product is being distributed through the company’s U.S.-based partner. Sonoma’s antimicrobial hydrogel aims to address diaper rash issues for infants and children. These recent developments highlight the company’s ongoing efforts to increase its market presence in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.